United Therapeutics Corporation revenue by segment UTHR

Annual Quarterly

United Therapeutics Corporation splits its revenue into 7 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Tyvaso DPI at $378.5 million, 45% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Revenue	3,188	832	783	782	790	800	799	794	736
Tyvaso	—	—	—	—	—	—	—	466 share 58.7%	—
Tyvaso DPI	1,374 +12.0% share 43.1%	378 +12.6% share 45.5%	327 +3.6% share 41.7%	330 share 42.3%	339 +23.9% share 42.8%	336 share 42.1%	315 share 39.5%	—	273 share 37.1%
Orenitram	528 +9.1% share 16.5%	145 +10.6% share 17.4%	126 +1.5% share 16.0%	136 +12.3% share 17.4%	121 +12.4% share 15.3%	131 share 16.4%	124 share 15.5%	121 share 15.2%	108 share 14.6%
Nebulized Tyvaso	504 -16.3% share 15.8%	125 share 15.1%	126 -18.4% share 16.1%	127 -22.3% share 16.3%	126 -11.9% share 15.9%	—	154 share 19.3%	164 share 20.6%	143 share 19.4%
Remodulin	503 -5.7% share 15.8%	122 -3.1% share 14.7%	126 -6.2% share 16.1%	127 -8.4% share 16.2%	128 -4.8% share 16.2%	126 share 15.7%	135 share 16.9%	138 share 17.4%	134 share 18.3%
Unituxin	233 +0.6% share 7.3%	52 +9.2% share 6.3%	65 +11.6% share 8.3%	54 -7.9% share 6.9%	62 -7.7% share 7.9%	48 share 6.0%	58 share 7.3%	58 share 7.3%	68 share 9.2%
Adcirca	22 -18.6% share 0.7%	4 -53.6% share 0.5%	7 +3.1% share 0.9%	3 -51.7% share 0.4%	8 +66.0% share 1.0%	10 share 1.2%	6 share 0.8%	6 share 0.8%	5 share 0.6%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: UTHR (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Silver Spring, MD
SEC filer status: Large accelerated filer
SEC CIK: 1082554

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.